European Archives - Page 295 of 1472 - European Medical Journal

HLTH Europe 2025 Interview: Nada Abedin

There are two sides to this. On one hand, I’ve been working in high-stakes specialties with fast-paced environments, such as emergency…

Steven Okoli

Hema Now: Episode 22: The State of Sickle Cell

Steven Okoli, Honorary Senior Clinical Lecturer at Imperial College London, shares how AI, advocacy, and stem cell trials are driving the next chapter in sickle cell care.

NHS Expands Access to Once-Daily Cystic Fibrosis Treatment

Hundreds of people with cystic fibrosis in England will now have access to a new once-daily triple therapy, expanding treatment to rare genetic types for the first time.

dementia

NHS Expands Access to Once-Daily Cystic Fibrosis Treatment

Hundreds of people with cystic fibrosis in England will now have access to a new once-daily triple therapy, expanding treatment to rare genetic types for the first time.

Peripheral Vision Training Improves Radiology Accuracy and Speed

Learn how visual training improves radiology accuracy and efficiency, with peripheral focus proving more impactful than central vision methods.

Hybrid Tumour-Immune Cells Found in Blood of Patients with Breast Cancer

Scientists have identified a rare and previously overlooked type of circulating tumour cell (CTC) in patients with metastatic breast cancer…

A colourful flat illustration of a woman in a lab coat looking down at a pestle and mortar, plants, pills and tinctures

Pharma’s role in the rise of wellness misinformation

Wellness trends are outpacing science and endangering lives. As trust in traditional medicine erodes, pharma must step in to correct the narrative.

Dapagliflozin Reverses Cardiac Fibrosis in Diabetic HFpEF, Study Finds

Dapagliflozin reverses myocardial fibrosis in HFpEF with diabetes, suggesting a disease-modifying effect.

Gut Microbiome Predicts Success of Peanut Immunotherapy

Peanut oral immunotherapy (POIT), which involves gradually increasing exposure to peanut protein, has shown promise, successfully desensitising 50–70% of patients.

EAN 2025 Interview: Jana Midelfart-Hoff

The most rewarding aspect is definitely the people you meet on the board. There are so many enthusiastic and extremely competent colleagues…